anticholesterolemics (Pfizer)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Nameanticholesterolemics (Pfizer)
Drug Alias Nameanticholesterolemics (Parke-Davis)atherosclerosis therapy (Parke-Davis)ACAT inhibitors (Parke-Davis)PD-140296PD-179468 +[6] 
ClassificationSmall molecules
Mechanisms of ActionAcyl coenzyme A:cholesterol acyltransferase inhibitors
TargetsAcyl coenzyme A:cholesterol acyltransferase
Therapy Area/IndicationsHypercholesterolemiaAtherosclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesParke-Davis CorpPfizer Inc
Active IndicationsN/A
Inactive IndicationsHypercholesterolemiaAtherosclerosis

Other Information

ATC CodeN/A
Related LinksN/A